Megapharm Ltd. has entered into an exclusive license and distribution agreement with Foresee Pharmaceuticals Co Ltd. for the commercialisation in Israel and the Palestinian Authority of Foresee Pharmaâââ¢s FP-001 program, LMIS (leuprolide mesylate injectable suspension) ready-to-use subcutaneous depot formulations. The agreement enables Megapharm and Foresee Pharma to license and distribute FP-001 in Israel.